medicare glp 1 This new program offers obesity drugs for $50 a month. Here’s what you need to know Medicare GLP-1 Bridge Program: What

Major segments are included in the report as indication, application, Distribution Channel, and regions

As a lower-cost way for a plan sponsor to help employees access medications that are available DTC, this approach could make it feasible to offer a benefit for the first time or to continue some form of support

Research shows that taking GLP-1 receptor agonists may increase a persons risk of developing certain vision problems, including NAION, which can cause sudden, painless vision loss in one eye due to reduced blood flow in the optic nerve

[46] After completing the SURPASS-2 trial (NCT03987919), the company announced in April 2022 that tirzepatide had successfully met its clinical endpoints in obese and overweight participants without diabetes

Helpful links and resources: Learn about our guests here: IG: @drkelleychew and @brightlineeating Sign up for Dr Lauren's Biohacking for the Rest of Us newsletter here